1 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
Follow CTCL: new trials by email Literature Review of CTCL trials Research Report on CTCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma FG-M131 - PTCL, TRBC1 ADC | Phase 1 / Phase 2 | Not yet recruiting | FutureGen Biopharmaceutical (Beijing) Co., Ltd | 110 | 2026-08-30 | 2026-09-02 |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL PTX-100 - CTCL | Phase 2 | Recruiting | Prescient Therapeutics, Ltd. | 115 | 2025-03-28 | 2026-09-09 |
| Ritlecitinib in CTCL Ritlecitinib - CTCL, Mycosis Fungoides | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2023-05-17 | 2025-07-18 |
| A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL BNZ132-1-40 - LGL Leukemia, CTCL | Phase 1 / Phase 2 | Completed | Bioniz Therapeutics | 50 | 2018-04-01 | 2021-05-25 |
Mycosis Fungoides (2) · Sezary Syndrome (2) · Leukemia, Large Granular Lymphocytic (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Recurrence (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma (2) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1)
Bioniz Therapeutics (1) · FutureGen Biopharmaceutical (Beijing) Co., Ltd (1) · Icahn School of Medicine at Mount Sinai (1) · Prescient Therapeutics, Ltd. (1)
United States (3) · Australia (1) · China (1) · France (1) · Italy (1)
Jonathan Brammer, MD, PhD (1) · Patrick Brunner, MD (1)